Skip to content
10-K

Annual Report

Cascadian Therapeutics, Inc.

0001193125-17-076986

← back to feed
Filed
Mar 9, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2016 · Mar 9, 2017 49.22M sh
Short Term Investments FY 2016 · Dec 31, 2015 $28.51M
Current Liabilities FY 2016 · Dec 31, 2015 $4.8M
Current Assets FY 2016 · Dec 31, 2015 $57.98M
Total Assets FY 2016 · Dec 31, 2015 $96.57M
Net Income FY 2016 · Dec 31, 2015 −$9.13M
Net Income FY 2016 · Sep 30, 2015 −$4.62M
Net Income FY 2016 · Jun 30, 2015 −$10.9M
Net Income FY 2016 · Mar 31, 2015 −$7.94M
Net Income FY 2016 · Dec 31, 2014 −$49.96M
Stock Issued FY 2016 · Feb 28, 2015 2.25M sh
Stock Issued restated FY 2016 · Sep 23, 2014 1.67M sh
Shares Diluted restated FY 2016 · Dec 31, 2014 12.94M sh
Capex FY 2016 · Dec 31, 2014 $380K
Sga Expense FY 2016 · Dec 31, 2014 $8.95M
Rd Expense FY 2016 · Dec 31, 2014 $41.88M
Operating Income FY 2016 · Dec 31, 2014 −$50.84M
Cash And Equivalents FY 2016 · Dec 31, 2013 $9.28M
Stockholders Equity FY 2016 · Dec 31, 2013 $71.55M